BioNexus Gene Lab Corp. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1287743,
    "name": "BioNexus Gene Lab Corp.",
    "stock_name": "BioNexus Gene Lab Corp.",
    "full_name": "BioNexus Gene Lab Corp.",
    "name_url": "stocks-analysis/bionexus-gene-lab-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.33",
    "chg": -0.02,
    "chgp": "-0.46%",
    "dir": -1,
    "prev_price": "4.35",
    "mcapval": "8.92",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Miscellaneous",
    "ind_code": 3205,
    "indexname": "S&P 500",
    "isin": "US0906282076",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "188.26 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bionexus-gene-lab-corp-1287743-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is BioNexus Gene Lab Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bionexus-gene-lab-corp-technically-bullish-or-bearish-3547888",
        "imagepath": "",
        "date": "2025-09-20 20:05:19",
        "description": "As of 5 September 2025, the technical trend for BioNexus Gene Lab Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe, bullish Bollinger Bands on both weekly and monthly timeframes, and a bullish On-Balance Volume (OBV) on both timeframes. The Dow Theory also indicates a mildly bullish position on both weekly and monthly charts. \n\nIn terms of performance, the stock has shown significant returns, with a year-to-date return of 103.79% compared to the S&P 500's 12.22%, and a one-year return of 36.01% versus the S&P 500's 17.14%...."
      },
      {
        "title": "Is BioNexus Gene Lab Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bionexus-gene-lab-corp-overvalued-or-undervalued-3544114",
        "imagepath": "",
        "date": "2025-09-20 18:38:11",
        "description": "As of 9 December 2022, the valuation grade for BioNexus Gene Lab Corp. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative valuation ratios and poor performance metrics. Key ratios include a Price to Book Value of 0.72, an EV to Sales ratio of 0.22, and a ROCE of -54.21%, all suggesting significant financial distress.\n\nIn comparison to peers, BioNexus Gene Lab Corp. has a less favorable EV to EBITDA of -0.95 compared to CervoMed, Inc. at -2.3987 and Team, Inc. at 9.7974, highlighting its weaker operational efficiency. Additionally, while the company has shown strong short-term returns, with a YTD return of 103.79% compared to the S&P 500's 12.22%, its long-term performance is concerning, with a 3Y return of -95.94% versus the S&P 500's 70.41%. This stark contrast reinforces the notion that the stock is curre..."
      }
    ],
    "total": 6,
    "sid": "1287743",
    "stock_news_url": "https://www.marketsmojo.com/news/bionexus-gene-lab-corp-1287743"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is BioNexus Gene Lab Corp. technically bullish or bearish?

2025-09-20 20:05:19

As of 5 September 2025, the technical trend for BioNexus Gene Lab Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe, bullish Bollinger Bands on both weekly and monthly timeframes, and a bullish On-Balance Volume (OBV) on both timeframes. The Dow Theory also indicates a mildly bullish position on both weekly and monthly charts. In terms of performance, the stock has shown significant returns, with a year-to-date return of 103.79% compared to the S&P 500's 12.22%, and a one-year return of 36.01% versus the S&P 500's 17.14%....

Is BioNexus Gene Lab Corp. overvalued or undervalued?

2025-09-20 18:38:11

As of 9 December 2022, the valuation grade for BioNexus Gene Lab Corp. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative valuation ratios and poor performance metrics. Key ratios include a Price to Book Value of 0.72, an EV to Sales ratio of 0.22, and a ROCE of -54.21%, all suggesting significant financial distress. In comparison to peers, BioNexus Gene Lab Corp. has a less favorable EV to EBITDA of -0.95 compared to CervoMed, Inc. at -2.3987 and Team, Inc. at 9.7974, highlighting its weaker operational efficiency. Additionally, while the company has shown strong short-term returns, with a YTD return of 103.79% compared to the S&P 500's 12.22%, its long-term performance is concerning, with a 3Y return of -95.94% versus the S&P 500's 70.41%. This stark contrast reinforces the notion that the stock is curre...

View All News